Is Corbus Pharmaceuticals a Buy Now? [The Motley Fool]
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
corbuspharma.com
Company Research
Source: The Motley Fool
Is Corbus Pharmaceuticals a Buy Now? It's been a little over a decade since Corbus Pharmaceuticals ( NASDAQ:CRBP Corbus has lenabasum in a late-stage pivotal trial as an anti-inflammation drug for patients with severe autoimmune conditions. Success could lead to billions in annual sales, but Corbus Pharmaceuticals has been trading at a market cap of just $77 million. Image source: Getty Images. Is this little biotech a bargain opportunity at recent prices, or a value trap to be avoided? Here's what you need to know about both sides of the argument. Reasons to buy The ongoing Resolve- trial will enroll around patients with systemic sclerosis, a severe and thankfully rare autoimmune disease. Around 00,000 people in the U.S., EU, and Japan are affected by systemic sclerosis, and positive mid-stage data suggests lenabasum resolves inflammation and reduces the formation of scar tissue or fibrosis. In 0, Corbus reported data from a phase Systemic sclerosis is the most advanced among four
Show less
Read more
Impact Snapshot
Event Time:
CRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
News
- Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual MeetingGlobeNewswire
- Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology [Seeking Alpha]Seeking Alpha
- Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength [Yahoo! Finance]Yahoo! Finance
- Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer [Yahoo! Finance]Yahoo! Finance
CRBP
Sec Filings
- 4/11/24 - Form 4
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form 8-K
- CRBP's page on the SEC website